BMO Capital Remains Bullish on Structure Therapeutics (GPCR), Cites Upcoming Trial Readouts

Core Insights - Structure Therapeutics Inc. (NASDAQ:GPCR) is recognized as a promising small-cap biotech stock with significant upside potential according to analysts [1] Group 1: Analyst Ratings and Price Targets - BMO Capital maintains an "Outperform" rating on Structure Therapeutics, setting a price target of $100, citing upcoming Phase 2b obesity trial readouts as a key factor for the company's competitive position in the weight-loss drug market [2] - The firm notes that easing expectations following Eli Lilly's recent data make Structure's results a critical benchmark [2] Group 2: Financial Performance - In Q3 2025, Structure Therapeutics reported a net loss of $65.7 million, an increase from $34 million in Q3 2024, with research costs reaching $59 million, expected to remain high due to upcoming trial spending [3] - The company reaffirmed that its ongoing obesity studies are on track for year-end [3] Group 3: Cash Position and Future Plans - Structure Therapeutics ended the quarter with a strong cash position of $799 million, which will support continued development and planned study initiations through 2026 [4] - The company focuses on developing oral small-molecule treatments for metabolic diseases [4]